🇪🇺EU · EMAWithdrawnATC: J07BX

Dengvaxia(chimeric yellow fever dengue virus serotype 1 (live, attenuated);chimeric yellow fever dengue virus serotype 2 (live, attenuated);chimeric yellow fever dengue virus serotype 3 (live, attenuated);chimeric yellow fever dengue virus serotype 4 (live, attenuated))

Dengue

Marketing Authorisation Holder: Sanofi Winthrop Industrie

EMA Authorisation: 12/12/2018

INN: dengue tetravalent vaccine (live, attenuated)

Indication

Dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4.2, 4.4 and 4.8). The use of Dengvaxia should be in accordance with official recommendations.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Dengvaxia — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Ask about Dengvaxia Create Free Account

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.